Corvus reports Q1 net loss of $7.9M; CPI-818 shows 6/13 ORR in ALC>900 TCL patients

Corvus Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.17

Net loss of $7.9M vs $8.3M in Q1 2022; cash & securities $34.5M as of March 31, 2023.
CPI-818 Phase 1/1b TCL: 2 CR, 1 nodal CR, 3 PR among 19 evaluable; 9 patients remain on therapy.
ALC>900 biomarker selected 6/13 ORR; median PFS 19.9 months for ALC>900 vs 2.1 months for <900.
CFO expects FY2023 net cash use of $19-22M; projected year-end cash of $20-23M funding into 2024.
Plans to meet with FDA in Q3 2023 to discuss potential registrational Phase 3 trial for CPI-818.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvus Pharmaceuticals, Inc. reported the three months ended March 31, 2023 results: net income $7.9 million.

Period: the three months ended March 31, 2023
Net income: $7.9 million
Result: reported results

Exact text from the filing

The net loss for the three months ended March 31, 2023 was $7.9 million compared to a net loss of $8.3 million for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-003041

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.